Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M

* Arbutus Biopharma press release [https://seekingalpha.com/pr/20446883-arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate] (ABUS [https://seekingalpha.com/symbol/ABUS]): Q4 GAAP EPS of -$0.17 misses by $0.13.
* Revenue of $14.08M (+128.2% Y/Y) beats by $13.47M.
* Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025.

MORE ON ARBUTUS BIOPHARMA

* Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [https://seekingalpha.com/article/4865237-arbutus-biopharma-stock-lnp-litigation-imdusiran-drive-near-term-catalysts]
* Moderna gains as Arbutus/ Genevant settlement removes major financial risk [https://seekingalpha.com/news/4560704-moderna-gains-arbutus-genevant-settlement]
* Moderna dealt blows in ongoing patent dispute with Arbutus [https://seekingalpha.com/news/4553214-moderna-dealt-blows-in-ongoing-patent-dispute-with-arbutus]
* Seeking Alpha’s Quant Rating on Arbutus Biopharma [https://seekingalpha.com/symbol/ABUS/ratings/quant-ratings]
* Historical earnings data for Arbutus Biopharma [https://seekingalpha.com/symbol/ABUS/earnings]